Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jankovic, J.
Right arrow Articles by Atassi, M. Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jankovic, J.
Right arrow Articles by Atassi, M. Z.
Related Collections
Right arrow Dystonia
Right arrow Botulinum toxin
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2006;67:2233-2235
© 2006 American Academy of Neurology
Brief Communications

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

J. Jankovic, MD, C. Hunter, RN, B. Z. Dolimbek, PhD, DSc, G. S. Dolimbek, MD, C. H. Adler, MD, PhD, A. Brashear, MD, C. L. Comella, MD, M. Gordon, MD, D. E. Riley, MD, K. Sethi, MD, C. Singer, MD, M. Stacy, MD, D. Tarsy, MD and M. Z. Atassi, PhD, DSc

From Baylor College of Medicine (J.J., C.H., B.Z.D., G.S.D., M.Z.A.), Houston, TX; Mayo Clinic Scottsdale (C.H.A.), Scottsdale, AZ; Indiana University School of Medicine (A.B.), Indianapolis, IN; Rush University Medical Center (C.L.C.), Chicago, IL; Long Island Jewish Medical Center (M.G.), New Hyde Park, NY; University Hospitals of Cleveland (D.E.R.), Cleveland, OH; Medical College of Georgia (K.S.), Augusta, GA; University of Miami (C.S.), Miami, FL; Barrow Neurologic Institute (M.S.), Phoenix, AZ; Beth Israel Deaconess Medical Center (D.T.), Boston, MA.

Address correspondence and reprint requests to Dr. Joseph Jankovic, Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030; e-mail: josephj{at}bcm.tmc.edu

In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

Disclosure: This study was sponsored by Allergan, Inc. Drs. Jankovic, Brashear, Gordon, and Sethi have received honoraria from Allergan, Inc. Drs. Jankovic, Atassi, Comella, B.Z. Dolimbek, Gordon, and Sethi have received grants in excess of $10,000 from Allergan, Inc. Drs. Hunter, Adler, Riley, Singer, G.S. Dolimbek, Stacy, and Tarsy have nothing to disclose.

Received March 21, 2006. Accepted in final form August 31, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.